Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI

Overview

Pacemaker requirement in the immediate post procedure phase following TAVI is approximately 20% depending on device type and patient characteristics. There is a signal from recent studies suggesting increased risk of sudden cardiac / unexplained death in the first 30-60 days. This study aims to address whether there is a mortality advantage to having a pacemaker in the short term

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 2016

Interventions

  • Device: Pacemaker

Arms, Groups and Cohorts

  • Those with pacemaker at discharge
    • Landmark analysis of early mortality dependant on pacemaker status at discharge
  • Those without pacemaker at discharge
    • Landmark analysis of early mortality dependant on pacemaker status at discharge

Clinical Trial Outcome Measures

Primary Measures

  • 30 day mortality
    • Time Frame: 30 dyas

Secondary Measures

  • 60 day mortality
    • Time Frame: 60 days

Participating in This Clinical Trial

Inclusion Criteria

  • All patients post TAVI Exclusion Criteria:

  • Nil

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Royal Sussex County Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: David Hildick-Smith, Consultant Cardiologist – Royal Sussex County Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.